65,437 trials
Hypertension · Left Ventricular Hypertrophy · Overweight
Primary: Change in Left Ventricular Mass Index (LVMI) From Baseline to End of Study (Week 36) — -5.51; -4.81; -5.61 g/m^2
Stomach Ulcer · Duodenal Ulcer
Primary: Number of Participants With Gastric Ulcer and/or Duodenal Ulcer — 15; 46 participants — p=<0.0001
Hypertension
Primary: Overall Percentage of Patients With Adverse Events — 76.2 percentage of patients
Hypercholesterolemia · Coronary Arteriosclerosis
Primary: Low Density Lipoprotein-cholesterol (LDL-C) at Baseline and After 6 Weeks of Treatment With Ezetimibe 10 mg Added to Atorvastatin 10 mg Versus Placebo Added to…
Migraine Disorders
Primary: Number of Participants Who Were Pain Free at 2 Hours Post-dose — 14; 28; 26; 36 participants — p=0.003
HIV Infections
Primary: Number of Participants With Human-immunodeficiency Virus- Ribonucleic Acid (HIV-RNA) < 50 Copies (c)/mL at Week 48 — 343; 338 Participants
Anemia · Hemosiderosis
Primary: The Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs) or Deaths — 85; 99; 36; 50 Participants
Systemic Lupus Erythematosus
Primary: Double Blind Period (DB); Number of Participants Experiencing a New SLE Flare — 94; 47 Participants
Rheumatoid Arthritis
Primary: Change in VO2 Max, Maximum Oxygen Uptake in ml/Min/kg is the Standard Index of Cardio-respiratory Fitness — 3.82; -0.44 ml/min/kg — p=0.002
Osteoporosis
Primary: Part 1: Urinary Excretion of Alendronate — 133.6; 132.2 μg
Headache
Primary: Number of Participants Who Report Moderate or Severe Pain Within 24 Hours of Emergency Department(ED) Discharge — 53; 6; 20 Participants
Hidradenitis Suppurativa
Primary: Percentage of Participants Achieving Clinical Response at Week 16 — 17.6; 9.6; 3.9 percentage of participants — p=0.022
Contraception
Primary: Mean Maximum Concentration (Cmax) of EE Incl. Bioequivalence (BE) Evaluation — 39.6; 41.9 pg/mL
Hypertension
Primary: Reduction in Systolic Blood Pressure and Diastolic Blood Pressure From Baseline to Study End — -28.5; -16.1 mmHg
Hypertension
Primary: Change in Mean Sitting Systolic Blood Pressure (MSSBP) From Baseline to End of Period 1 (Week 6) — -8.3; -10.3; -14.4 mm Hg — p=0.0990